TY - JOUR T1 - Atlas of axial spondyloarthritis in Spain 2017: Study design and population JO - Reumatología Clínica (English Edition) T2 - AU - Garrido-Cumbrera,Marco AU - Navarro-Compán,Victoria AU - Zarco,Pedro AU - Collantes-Estévez,Eduardo AU - Gálvez-Ruiz,David AU - Braçe,Olta AU - Chacón García,Jorge AU - Blanch Mur,Carles AU - Costa Ferrer,Angels AU - Hidalgo Vega,Alvaro AU - Plazuelo Ramos,Pedro AU - Gratacós Masmitja,Jordi SN - 21735743 M3 - 10.1016/j.reumae.2018.09.010 DO - 10.1016/j.reumae.2018.09.010 UR - https://www.reumatologiaclinica.org/en-atlas-axial-spondyloarthritis-in-spain-articulo-S2173574319300413 AB - ObjectiveAtlas of Axial Spondyloarthritis in Spain 2017 aims to better understand the reality of the patients suffering from this disease from an integrated approach. MethodsThe Atlas 2017 based its results on an extensive cross-sectional patient survey conducted in Spain (2016), validated by a multidisciplinary group of experts on spondyloarthritis. ResultsData from 680 patients with axSpA were obtained, most of them suffered from AS, were HLA-B27 positive, older than 45 years, and live as part of a couple. A large percentage had university studies, were disabled and members of a patient association. Patients reported a diagnostic delay of 8.5 years, high disease activity (BASDAI 5.5±2.2), moderate-important stiffness (61.0%), medium-high functional limitation (74.9%), and psychological distress (GHQ 5.7±4.5). A total of 54.7% reported taking NSAIDs, 28.4% DMARDs, 36.3% biological therapy and 32.2% were not receiving pharmacological treatment. ConclusionsThe Atlas survey data reveals still a long diagnostic delay, high disease activity, psychological distress, while an important proportion could be undertreated. ER -